[1]
|
N. Grenier and P. Brader, “Principles and Basic Concepts of Molecular Imaging,” Pediatric Radiology, Vol. 41, No. 2, 2011, pp. 144-160. doi:10.1007/s00247-010-1835-z
|
[2]
|
J. C. Gore, H. C. Manning, C. C. Quarles, et al., “Magnetic Resonance in the Era of Molecular Imaging of Cancer,” Magnetic Resonance Imaging, Vol. 29, No. 5, 2011, pp. 587-600. doi:10.1016/j.mri.2011.02.003
|
[3]
|
M. H. Michalski and X. Chen, “Molecular Imaging in Cancer Treatment,” European Journal of Nuclear Medicine and Molecular Imaging, Vol. 38, No. 2, 2011, pp. 358-377. doi:10.1007/s00259-010-1569-z
|
[4]
|
M. R. Makowski, A. J. Wiethoff, C. H. Jansen, et al., “Mo lecular Imaging with Targeted Contrast Agents,” Topics in Magnetic Resonance Imaging, Vol. 20, No. 4, 2009, pp. 247-259. doi:10.1097/RMR.0b013e3181ea28b1
|
[5]
|
M. A. Pysz, S. S. Gambhir and J. K. Willmann, “Molecular Imaging: Current Status and Emerging Strategies,” Clinical Radiology, Vol. 65, No. 7, 2010, pp. 500-516.
doi:10.1016/j.crad.2010.03.011
|
[6]
|
R. F. Minchin and D. J. Martin, “Nanoparticles for Molecular Imaging—An Overview,” Endocrinology, Vol. 151, No. 2, 2010, pp. 474-481. doi:10.1210/en.2009-1012
|
[7]
|
M. Wen, B. Li, W. Bai, et al., “Application of Atomic Force Microscopy in Morphological Observation of Antisense Probe Labeled with Magnetism,” Molecular Vision, Vol. 14, No. 1, 2008, pp. 114-117.
|
[8]
|
M. Wen, B. Li, Y. Ouyang, et al., “Preparation and Quality Test of Superparamagnetic Iron Oxide Labeled Antisense Oligodeoxynucleotide Probe: A Preliminary Study,” Annals of Biomedical Engineering, Vol. 37, No. 6, 2009, pp. 1240-125. doi:10.1007/s10439-009-9683-4
|
[9]
|
R. Qiao, J. Zeng, Q. Jia, et al., “Magnetic Iron Oxide Nanoparticle—An Important Cornerstone of MR Molecular Imaging of Tumors,” Acta Physico-Chimica Sinica, Vol. 28, No. 5, 2012, pp. 993-1011.
|
[10]
|
K. Chen and X. Chen, “Design and Development of Molecular Imaging Probes,” Current Topics in Medicinal Chemistry, Vol. 10, No. 12, 2010, pp. 1227-1236.
doi:10.2174/156802610791384225
|
[11]
|
P. Padmanabhan, J. Goggi, R. Bejot, et al., “Molecular Targeting of Breast Cancer: Imaging and Therapy,” Current Pharmaceutical Biotechnology, Vol. 12, No. 4, 2011, pp. 528-538. doi:10.2174/138920111795163959
|
[12]
|
J. Capala and K. Bouchelouche, “Molecular Imaging of HER2-Positive Breast Cancer: A Step toward an Individualized Image and Treat Strategy,” Current Opinion in Oncology, Vol. 22, No. 6, 2010, pp. 559-566.
doi:10.1097/CCO.0b013e32833f8c3a
|
[13]
|
M. E. Seaman, G. Contino, N. Bardeesy, et al., “Molecular Imaging Agents: Impact on Diagnosis and Therapeutics in Oncology,” Expert Reviews in Molecular Medicine, Vol. 12, 2010, p. e20. doi:10.1017/S1462399410001511
|
[14]
|
J. W. Bulte and D. L. Kraitchman, “Iron Oxide MR Contrast Agents for Molecular and Cellular Imaging,” NMR in Biomedicine, Vol. 17, No. 7, 2004, pp. 484-499.
doi:10.1002/nbm.924
|
[15]
|
H. Ittrich, C. Lange, F. Togel, et al., “In Vivo Magnetic Resonance Imaging of Iron Oxide-Labeled, Arterially Injected Mesenchymal Stem Cells in Kidneys of Rats with Acute Ischemic Kidney Injury: Detection and Monitoring at 3T,” Journal of Magnetic Resonance Imaging, Vol. 25, No. 6, 2007, pp. 1179-1191.
doi:10.1002/jmri.20925
|